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Abstract
Introduction: Individuals with osteoarthritis (OA) show increased morbidity and mortality. Telomere length, a measure of cellular
aging, predicts increased morbidity and mortality. Telomeres shorten with persisting biological and psychosocial stress. Living with
chronic OA pain is stressful. Previous research exploring telomere length in people with OA has produced inconsistent results.
Considering pain severity may clarify the relationship between OA and telomeres.
Objectives:Wehypothesized that individuals with highOA chronic pain severity would have shorter telomeres than thosewith no or
low chronic pain severity.
Methods: One hundred thirty-six adults, ages 45 to 85 years old, with and without symptomatic knee OA were included in the
analysis. Peripheral blood leukocyte telomere length wasmeasured, and demographic, clinical, and functional data were collected.
Participants were categorized into 5 pain severity groups based on an additive index of frequency, intensity, time or duration, and
total number of pain sites (FITT). Covariates included age, sex, race or ethnicity, study site, and knee pain status.
Results: The no or low chronic pain severity group had significantly longer telomeres compared with the high pain severity group,
P5 0.025. A significant chronic pain severity dose response emerged for telomere length,P5 0.034. The FITT chronic pain severity
index was highly correlated with the clinical and functional OA pain measures. However, individual clinical and functional measures
were not associated with telomere length.
Conclusion: Results demonstrate accelerated cellular aging with high knee OA chronic pain severity and provide evidence for the
potential utility of the FITT chronic pain severity index in capturing the biological burden of chronic pain.
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1. Introduction
Approximately 22.7% of adults in the United States are
diagnosed with osteoarthritis (OA).4,32,44 Osteoarthritis is not
only a leading cause of disability, it is also associated with
increased morbidity and mortality11,23,47,56,57; OA may also
contribute toward a biological footprint. Telomere length is
a marker of cellular aging. Telomeres are the DNA repeats that
provide the protective covers at the ends of chromosomes, which
attrite with cell divisions, a natural process of aging.7 Leukocyte
telomere length (LTL) is negatively associated with biological and
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psychosocial stress13,41 and is predictive of morbidity and
mortality.7,16,51
The relationship between LTL and OA is unclear.55,60 In
a population-based study of women, LTL was shorter in
individuals with hand OA than those without the condition and
negatively associated with radiographic disease severity.60 By
contrast, a second study found no differences in LTL between
individuals diagnosed with OA and healthy controls.55 Sample
size, type, and extent of OA are a few factors likely contributing to
these discrepancies. In addition, based on LTL studies across
differing health conditions, clinical factors such as the severity and
persistence are important to consider.
Leukocyte telomere length is indicated as a “downstream”
marker of cumulative, persistent, biological, or psychosocial
stress.41 Qualities of the “stressor” such as frequency, intensity,
and duration seem to be particularly relevant in driving the
biological burden of various life experiences.12,15,25,37,51,59 Pain is
stressful. Over time, OA pain extends to other body regions and is
associated with hyperalgesia, allodynia, and decreased efficiency
of endogenous inhibitory mechanisms.19,23,29,36,43,50 Decreased
physical activity and a decline in functioning are key features in
OA, both of which are primarily attributable to pain.23,42
A few publications have explored the possible relevance of LTL
in chronic pain conditions.22,52,54With an improved understanding
of stress-related qualities that contribute to a cumulative biological
burden (frequency, intensity, duration, and type or extent of stress)
28 and the limitation of current pain measures in capturing duration
beyond 3 to 6 months, we recently investigated a new measure of
chronic pain severity.53 The chronic pain severity index is an
additive index comprising 4 pain characteristics (FITT): (1)
frequency of pain (intermittent or persistent); (2) intensity of pain;
(3) time (duration) of chronic pain; and (4) total number of pain sites.
In a large population study of individuals endorsing chronic pain,
the chronic pain severity index was positively associated with
biological burden, and the combined index appears to be a better
predictor compared with individual pain domains.53
The purpose of this study was to investigate the relationship
between chronic pain severity and LTL in individuals with and
without symptomatic knee OA. We hypothesized that (1)
individuals with high chronic knee pain severity would have
shorter telomeres compared with individuals with no or low
chronic knee pain severity, (2) the individual FITT domains would
not be associated with LTL, (3) the FITT index would be
associated with OA pain and functioning measures, and (4) OA
pain and functioningmeasureswould not be associatedwith LTL.
2. Methods
2.1. Study design
Participants were recruited for a cross-sectional study from the
communities surrounding the University of Florida (UF) and the
University of Alabama at Birmingham (UAB) from 2010 to 2013.
Participants involved in the current investigation are from a larger
study titled Understanding Pain and Limitations in Osteoarthritic
Disease (UPLOAD), which involved a biopsychosocial investiga-
tion of ethnically diverse individuals with andwithout symptomatic
knee OA, see Table 1 for inclusion and exclusion criteria.
Participants with available baseline telomere length measures
and complete data on the FITT chronic pain severity questions
(described below) were considered in the current investigation.
All procedures described were reviewed and approved by the
University of Florida and University of Alabama at Birmingham
institutional review boards.
2.2. Participants
With an initial sample size of 229, 138 individuals had complete FITT
data and were eligible for inclusion in the current analysis. Two
individuals had conflicting phenotyping data and were excluded
resulting in a sample size of 136 adults aged 45 to 85 with and
without symptomatic kneeOApain. Themeasures andprocedures
described are limited to those included in the current investigation.
Inclusion and exclusion criteria are listed in Table 1. After
a phone screening,49 participants were seen for 2 appointments.
All measureswere typically collectedwithin a 2- to 3-week period.
A health assessment and physical examination were completed,
knee radiographs taken, and Kellgren Lawrence scores were
determined.1 Demographics and health history information were
collected. Additional measures are described below.
2.3. Clinical pain and functioning measures
Participants completed self-report measures of clinical pain
and functional limitations. The Western Ontario and McMaster
Universities Index of Osteoarthritis (WOMAC) is a 24-item scale
assessing knee OA symptoms in the last 48 hours. A 5-point
Likert scale was used with items ranging from 0 to 4 (higher
scores reflect greater symptom severity). Three subscales
comprise the WOMAC, including pain during activities (5
items), daytime stiffness (2 items), and impairments in physical
function (17 items).6 The Graded Chronic Pain Scale (GCPS)
consists of 7 items (rated on a 0-10 scale) and examines pain
severity and disability over the last 6 months. Participants rate
the intensity of their current knee pain and their worst and
average knee pain during the previous 6months (characteristic
pain intensity score). A disability score is also obtained by
having participants rate the degree to which their knee pain
interfered with daily activities during the last 6 months. Items
are averaged and multiplied by 10 to generate index scores for
characteristic pain intensity and disability, with higher scores
indicating greater symptoms. Disability points are computed
by adding points for disability days over the last 6 months with
the disability score. The overall pain grade is determined by
characteristic pain intensity and disability points and range
Table 1
Inclusion and exclusion criteria.
Exclusion Criteria
Prosthetic knee replacement or nonarthroscopic surgery to the symptomatic
knee
Serious medical conditions (eg, uncontrolled hypertension $ 150/95, heart
failure, history of acute myocardial infarction)
Peripheral neuropathy
Systemic rheumatologic disorders (eg, rheumatoid arthritis, systemic lupus
erythematosus, fibromyalgia)
Daily opioid use
Mini–Mental Status Examination (MMSE) score #22
Excessive anxiety regarding protocol procedures (eg, intravenous catheter
insertion, experimental pain procedures)
Psychiatric hospitalization within the preceding year
General inclusion criteria
Between the ages of 45 and 85
Self-identified as either African American or non-Hispanic white
Knee osteoarthritis screening questions46
During the last 4 wk, have you had knee pain on most days?
During the last 4 wk, have you had knee pain while climbing down stairs or
walking down slopes?
During the last 4 wk, have you had swelling in one or both knees?
Do you have knee osteoarthritis? (If you do, was the diagnosis made by
a rheumatologist or a general practitioner?)
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from 0 to 4.58 Physical function was assessed with the Short
Physical Performance Battery (SPPB), which includes tasks
measuring standing balance, 4-m gait speed, and chair rising.
Ranging from 0 to 12, a single summary performance score is
calculated with lower scores indicating greater functional
limitation.20,21
2.4. Chronic pain severity
Pain domains of frequency of knee pain, intensity of knee pain,
duration of knee pain on most days (time), and total number of
pain sites were assessed. Knee pain frequency is a categorical
variable (knee pain on most days, no or yes). Median splits were
computed for the other 3 variables. Computation of the median
splits for characteristic knee pain intensity and knee pain time
(duration) were limited to those reporting knee pain in the overall
sample (n 5 169) and based on available data for each variable.
Of note, the cut points incorporated in the study align for average
pain intensity in adults with knee and hip OA reported by Kapstad
and colleagues:1 to 45mild pain,.4 to 65moderate pain, and
.6 to 10 5 severe pain.24 Thus, the cut point in our article falls
between the “no to mild pain” and “moderate to severe pain.” In
addition, the cut point is similar to the average pain intensity cut
point incorporated in the FITT index in the previously reported
population-based study.53
A median split for total number of pain sites was computed
for the overall sample of those with and without knee pain (n5
229, median of 3) and for the knee pain group only (median of
4). Noteworthy, Lacey and colleagues reported that the
median number of pain sites lasting 1 day or more in
the previous 4 weeks in a community-based group of adults
in the United Kingdom$50 years of age was 4.31 Similarly, the
cut point for the total number of pain sites incorporated in the
FITT index in the previously reported population-based study
was 3 or less and 4 or greater.53 In this study, the total number
of pain sites with pain more days than not over the last 3
months was defined as 0 to 3 and 4 or greater. Once median
splits were computed, an additive index was compiled as
previously described,53 see Table 2.
2.5. Telomere length analysis
A blood sample was collected during the second study session
and placed on ice. It was centrifuged at 4˚C for 10 minutes at
3000 rpm. Once a sample was received, the blood was mixed
with 13 phosphate-buffered saline (PBS), layered onto a volume
of Lymphoprep solution that was contained in a centrifuge tube.
After centrifugation, the lymphocyte band was separated,
washed, and centrifuged to form a pellet. The pellet was
resuspended in 13 PBS, and the sample was stored at 280˚C.
The DNA isolation was achieved using the Qiagen FlexiGene kit.
Lysis buffer was added to the sample before being mixed and
centrifuged. The resulting pellet was resuspended in denaturation
buffer containing protease and incubated. DNA was then
precipitated, washed, centrifuged, and resuspended in hydration
buffer. Telomere length was analyzed by the Blackburn Lab,
University of California San Francisco.34
The telomere length assay is adapted from the published
original method by Cawthon.10,34 The telomere thermal cycling
profile consists of the following—Cycling for T (telomic) poly-
merase chain reaction (PCR): 96˚C for 1 minute; denature at 96˚C
for 1 second, anneal or extend at 54˚C for 60 seconds, with
fluorescence data collection, 30 cycles. Cycling for S (single-copy
gene) PCR: PCR: 96˚C for 1 minute; denature at 95˚C for 15
seconds, anneal at 58˚C for 1 second, extend at 72˚C for 20
seconds, 8 cycles; followed by denature at 96˚C for 1 second,
anneal at 58˚C for 1 second, extend at 72˚C for 20 seconds, hold
at 83˚C for 5 seconds with data collection, 35 cycles. The primers
for the telomere PCR are tel1b [59-CGGTTT(GTTTGG)5GTT-39],
used at a final concentration of 100 nM, and tel2b [59-GGCTTG
(CCTTAC)5CCT-39], used at a final concentration of 900 nM. The
primers for the single-copy gene (human beta globin) PCR are
hbg1 [59 GCTTCTGACACAACTGTGTTCACTAGC-39], used at
a final concentration of 300 nM, and hbg2 [59-CACCAACTT-
CATCCACGTTCACC-39], used at a final concentration of 700
nM. The final reaction mix contains 20 mM Tris-HCl, pH 8.4;
50 mMKCl; 200 mM each dNTP; 1% DMSO; 0.4x Syber Green I;
22 ng E. coli DNA per reaction; 0.4 Units of Platinum Taq DNA
polymerase (Invitrogen Inc, Waltham, MA) per 11 mL reaction; 6
ng of genomic DNA. Tubes containing 26, 8.75, 2.9, 0.97, 0.324,
and 0.108 ng of a reference DNA (pooled samples of leukocyte
genomic DNA from 100 female donors) are included in each PCR
run so that the quantity of targeted templates in each research
sample can be determined relative to the reference DNA sample
by the standard curve method. The same reference DNA was
used for all PCR runs.
To control for interassay variability, 8 control DNA samples
are included in each run. In each batch, the telomere to single-
copy gene (T/S) ratio of each control DNA is divided by the
average T/S for the same DNA from 10 runs to obtain
a normalizing factor. This is performed for all 8 samples, and
the average normalizing factor for all 8 samples is used to
correct the participant DNA samples to obtain the final T/S ratio.
The T/S ratio for each sample was measured twice. When the
duplicate T/S value and the initial value vary by more than 7%,
the sample was run the third time and the 2 closest values were
reported. The average coefficient of variation for this study is
1.9%. The laboratory personnel who performed the assays
received deidentified blood samples and were blind to de-
mographic and clinical data.
To determine the conversion factor for the calculation of
approximate base pair telomere length from T/S ratio, the above
method was used to determine the T/S ratios, relative to the
same reference DNA, for a set of genomic DNA samples from
Table 2
Chronic pain severity pain domains and FITT groups.
Pain domains Question Median and
score
Frequency Do you currently experience knee pain on
most days?
0 5 no
1 5 yes
Intensity GCPS characteristic pain intensity (current
1 worst1 average pain over last 6 mo/3
3 10)
0 5 0–47
1 5 48 –100
Time or duration How long have you experienced knee pain
on most days (in months)?
0 5 0–23 mo
15 24–360mo
Total number of
pain sites
Number of body regions with pain more
days than not over the last 3 months
0 5 0–3
1 5 4–18
FITT Groups Classification Domain total
1 No or low pain 0
2 Mild pain 1
3 Moderate pain 2
4 Moderate to high pain 3
5 High pain 4
GCPS, Graded Chronic Pain Scale.
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the human fibroblast primary cell line IMR90 at different
population doublings, as well as with the telomerase protein
subunit gene (hTERT) transfected into a lentiviral construct. The
mean terminal restriction fragment (TRF) length from these DNA
samples was determined using Southern blot analysis, and the
slope of the plot of mean TRF length vs T/S for these samples
served as the conversion factor for calculation of telomere
length in base pairs from the T/S ratio. The equation for
conversion from T/S ratio to base pairs for this study was base
pairs 5 3274 1 2413 3 (T/S).
2.6. Data analysis
Descriptive analyses for the categorical and continuous variables
were completed. Differences by chronic pain severity (FITT)
groups were tested using either analysis of variance F-test or x2
test. Pearson and Spearman correlational analyses were
calculated between telomere length and the following variables:
age, race or ethnicity (African American, non-Hispanic whites),
sex, waist–hip ratio (WHR), employment (8 categories), exercise
($1 time a week or#1 time a week), smoking status (nonsmoker
or current smoker), comorbidities (cumulative total past and
cumulative total current), education (#high school or $some
college), annual income (1–10 categorical), and Kellgren
Lawrence knee OA radiograph score (0–4). An analysis of
covariance was conducted to compare the no or low chronic
pain severity group (FITT 1) with the high chronic pain severity
group (FITT 5) adjusting for primary covariates which included
age, race or ethnicity, sex, study site, and knee pain status.
Secondary analyses for additional covariates were completed,
which were selected based on variables associated with
telomere length after controlling for age which was limited to
WHR. Linear regression models were used to conduct model-
based tests for analyses of FITT domains and FITT as an interval
variable predicting telomere length and for clinical and functional
pain measures predicting FITT and telomere length adjusting for
primary and secondary covariates. The data analysis was
conducted using SAS 9.4.
3. Results
3.1. Demographics and clinical and functional descriptors
by FITT
Tables 2 and 3 provide a descriptive overview across de-
mographic, biobehavioral, and clinical pain and functional
measures by the FITT chronic pain severity groups. Telomere
length was correlated with age (r520.398, P, 0.0005); race or
ethnicity (r520.229, P5 0.007); WHR (r520.222, P5 0.009);
past comorbidities (rho 520.191, P 5 0.026), and employment
status (rho 5 20.219, P 5 0.01). Telomere length was not
Table 3
FITT groups by demographics, bio-behavioral measures, and FITT domains.
FITT P
1 (n 5 21) 2 (n 5 17) 3 (n 5 22) 4 (n 5 41) 5 (n 5 35)
Demographics
Age, mean (SD), y 60.43 (7.74) 56.88 (8.92) 57.14 (8.03) 57.66 (7.79) 54.11 (8.27) 0.081
Race/Ethnicity, % 0.008
African Americans 33.33 58.82 54.55 41.46 77.14
Non-Hispanic Whites 66.67 41.18 45.45 58.54 22.86
Gender, % 0.789
Female 76.19 70.59 68.18 65.85 60.00
Male 23.81 29.41 31.82 34.15 40.00
Site, % ,.0001
UF 90.48 76.47 54.55 29.27 40.00
UAB 9.52 23.53 45.45 70.73 60.00
Employment, % 0.896
Employed 47.62 52.94 54.55 60.98 54.29
Not employed 52.38 47.06 45.45 39.02 45.71
Marital Status, % 0.638
Married 33.33 35.29 45.45 46.34 31.43
Not married 66.67 64.71 54.55 53.66 68.57
Bio-behavioral
BMI, mean (SD), kg/m2 25.85 (6.01) 30.41 (6.72) 31.03 (8.03) 31.15 (6.38) 34.94 (10.51) 0.002
Smoking, % 0.643
Non-smoker 55.00 47.06 50.00 53.66 40.00
Former smoker 25.00 29.41 36.36 19.51 22.86
Current smoker 20.00 23.53 13.64 26.83 37.14
Exercise frequency, % 0.511
,1 time/wk 20.00 52.94 27.27 26.83 40.00
1–3 times/wk 60.00 29.41 45.45 51.22 40.00
$4 times/wk 20.00 17.65 27.27 21.95 20.00
KL scores, mean (SD) 0.43 (0.75) 0.93 (1.22) 1.35 (1.42) 1.38 (1.48) 1.68 (1.59) 0.004*
FITT Domains
Frequency, %
Yes 0 41.18 86.36 100 100 ,0.0001
No 100 58.52 13.64 0 0
GCPS CPI 13.33 33.33 46.67 50 73.33 ,0.0001
Time/Duration 0 0 12 36 50 ,0.0001
Total Pain Sites 1 3 3 5 7 ,0.0001
GCPS CPI, Graded Chronic Pain Scale Characteristic Pain Intensity; KL, Kellgren Lawrence score.
* Spearman’s rho.
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associated with Kellgren Lawrence knee OA radiograph scores
on the most affected knee (rho 5 20.094, P 5 0.311).
3.2. FITT groups and telomere length
The no or low FITT group had significantly longer telome-
res compared with the high chronic pain severity FITT
group (P 5 0.025), see Figure 1. These findings persisted with
a secondary analysis with WHR added in the model (P5 0.036).
3.3. FITT domains, FITT, and telomere length
Linear regression analyses were conducted with the individual
FITT components and primary covariates (age, race or ethnicity,
sex, study site, and knee pain status) as predictor variables.
These analyses showed that individual FITT domains were not
predictive of telomere length (all P . 0.05). An additional linear
regression analysis was completed with FITT index as a numer-
ical predictor with primary covariates in the model. This analysis
showed that FITT significantly predicted telomere length (P 5
0.034), and this relationship persisted with the addition of WHR
in the model (P 5 0.048).
3.4. FITT groups and clinical and functional measures
FITT was significantly associated with all WOMAC and GCPS
measures (all P , 0.0001) and with performance on the SPPB
Chair Stand (P 5 0.02), but not with other SPPB subscales and
total, Table 4. These findings, with the exception of the SPPB
Chair Stand, persisted after controlling for WHR and incorporat-
ing Bonferroni correction adjustments.
3.5. Clinical or functional knee osteoarthritis measures and
telomere length
The WOMAC, SPPB, and GCPS and associated subscales were
not associated with telomere length (all P . 0.07), Table 5.
4. Discussion
There are a number of key findings from our investigation. First,
as hypothesized, individuals with high knee OA chronic pain
severity based on an FITT index had shorter telomeres
compared with individuals with no/low knee OA chronic pain
severity. Second, as anticipated, the individual FITT domains
were not associated with telomere length. However, the
combined FITT index captures a cumulative contribution from
each domain that has an additive predictive value as demon-
strated in a significant dose–response relationship. Third, the FITT
index was highly associated with recognized and frequently used
measures of OA pain and functioning. However, recognized and
frequently used measures of OA pain and functioning were not
associated with telomere length. Our findings suggest that the
FITT chronic pain severity index seems to capture the biological
interface of knee OA chronic pain severity more effectively than
commonly used clinical and functional measures of OA which
assess symptom severity over a shorter duration (48 hours to 6
months) and do not include measures of frequency or extent of
body sites with pain.
4.1. FITT groups and telomere length
A number of studies have indicated group differences in telomere
length when phenotypic extremes with persisting duration are
compared.12,37,59 Similarly, our findings demonstrate that telo-
mere length differed in individuals with chronic pain–related
phenotypic extremes: no/low chronic knee pain severity
Table 4
FITT groups by clinical and functional measures: unadjusted mean and SD with adjusted group comparisons.
Clinical measures FITT
1 (n 5 21) 2 (n 5 17) 3 (n 5 22) 4 (n 5 41) 5 (n 5 35) P
WOMAC
Pain 1.67 (2.39) 4.76 (2.41) 6.14 (3.36) 7.56 (3.47) 10.26 (3.73) ,0.0001
Stiffness 0.90 (1.45) 2.18 (1.13) 2.86 (1.52) 4.27 (1.63) 5.31 (1.81) ,0.0001
Physical function 6.00 (7.54) 16.59 (9.09) 17.86 (9.77) 26.34 (12.31) 35.66 (13.4) ,0.0001
Total 8.57 (10.26) 23.53 (11.87) 26.86 (12.8) 38.17 (16.54) 51.23 (17.88) ,0.0001
GCPS
CPI 11.75 (10.63) 35.29 (18.49) 48.48 (17.17) 53.17 (15.11) 72.57 (14.14) ,0.0001
Disability 0 (0) 0.94 (1.53) 2.00 (1.9) 2.02 (1.75) 3.60 (1.91) ,0.0001
Pain grade 0.71 (0.46) 1.38 (0.96) 2.10 (1.14) 2.15 (0.99) 3.06 (0.87) ,0.0001
SPPB
Chair stand 3.00 (0.84) 2.59 (1.33) 2.73 (1.39) 2.66 (1.32) 2.17 (1.44) 0.02
Gait 3.71 (0.72) 3.82 (0.39) 3.41 (1.01) 3.59 (0.84) 3.34 (1) 0.47
Balance 3.86 (0.36) 3.82 (0.39) 3.73 (0.94) 3.9 (0.3) 3.74 (0.85) 0.77
Total 10.57 (1.03) 10.24 (1.48) 9.86 (2.53) 10.15 (1.84) 9.26 (2.25) 0.12
CPI, Characteristic Pain Intensity; GCPS, Graded Chronic Pain Scale; SPPB, Short Physical Performance Battery; WOMAC, Western Ontario and McMaster Universities Index of Osteoarthritis. P-value reflects adjusted
comparison controlling for age, race, sex, site, and knee pain status.
Figure 1. Telomere length by FITT groups—groups defined by combined
scores for frequency, intensity, and time or duration of knee pain on most
days, and total number of pain site. Covariates in the model: age, race or
ethnicity, sex, site, and knee pain status. *Significant difference for FITT 1
and FITT 5, P 5 0.025.
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compared with those with high chronic knee pain severity. This
association persisted with secondary covariates in the model.
Importantly, the observed difference in telomere length reflects an
increase of approximately 16 years of accelerated aging between
the no or low and moderate or high and high severity groups.
Importantly, in this study, telomere length was appropriately
associatedwith age, race, andWHR. As joint changes in the knee
can occur without indications of pain and functional limita-
tions,9,17 the lack of association between Kellgren Lawrence
scores and telomere length is not surprising.
4.2. FITT domains and telomere length
A burgeoning body of evidence indicates the importance of
considering frequency, intensity, duration, and extent or severity
of stress in the evaluation of physiological dysregulation and
pain-related biological and health-related changes.25,33,38 For
example, pain intensity and pain duration contribute toward
the functional limitations and disability in individuals with knee
OA23 and predict functional and structural changes in the
brain.3,18,30 In addition, pain intensity and number of pain sites
are predictive of mortality.40,56 Likewise, pain frequency con-
tributes to the biological burden of pain. Leistad and colleagues
demonstrated that after an acute stressor, individuals with
chronic pain compared with those with episodic pain demon-
strated dysregulated stress system responses.33 Pain frequency
has also been linked to pain-related changes in the brain. In
individuals with chronic migraines for 3 years or more, individuals
with low-frequency migraines had greater bilateral hippocampal
volume comparedwith thosewith high-frequencymigraines, who
also demonstrated decreased functional connectivity between
the hippocampus and pain processing regions.38 Hence, it
seems that episodic or intermittent pain does not produce the
same biological consequences as persisting or high-frequency
pain.
Accelerated cellular aging as measured by telomere length
has been investigated across an extensive array of health
conditions and behavioral and psychosocial factors, and these
studies demonstrate similar findings regarding frequency,
intensity or severity, and duration of the stressor as described
above. Consistent with theoretical understanding of telomere
biology, short-term chronic stress in the range of 3 months is
anticipated to facilitate telomere lengthening.5 In addition,
intermittent stress in the case of exercise is associated
with longer telomeres.37,46 Reduced telomere length has
been repeatedly shown for a high “stressed” group compared
with healthy controls when the high stress group comprises
individualswhohave experienced frequent, persistingduration, and
moderate-to-high stress.12,15,59 Failure to adequately characterize
various stressors (frequency, intensity, duration, and severity) may
explain inconsistencies in previous clinical investigations of
telomere length.39,48,55 Importantly, our findings indicate that the
additive combination of factors rather than any individual dimension
(frequency, intensity, time or duration, and total number of pain
sites) is negatively associated with telomere length. Similar patterns
have emerged in other lines of investigation.2,30,53
4.3. Clinical and functional knee osteoarthritis measures,
FITT, and telomere length
Although FITT was highly correlated with the OA clinical and
functional measures, the clinical and functional measures were
not associated with telomere length. The WOMAC is a frequently
used measure that assesses lower extremity pain and function
over a timeframe of 48 hours. It is designed to capture recent pain
and, although correlated with a measure of chronic pain (GCPS),
it will capture dynamic pain experiences and may poorly reflect
other characteristics of chronic pain such as duration, frequency,
and extent of body pain.
The SPPB is a functional screening measure and in our sample
showed a limited score range. Although correlated with clinical
measures of knee pain, it is a measure of current functional
performance that does not capture features of clinical pain
(frequency, intensity, duration, and body sites with pain). The
GCPS is a well-recognized measure of chronic pain evaluating
intensity of pain and pain-related disability over the last 6 months.
However, it may not accurately reflect the overall duration of pain
beyond 6 months and does not capture the frequency of pain
experience or the extent of pain across other areas of the body.
Thus, the findings that telomere length is not associated with the
WOMAC, SPPB, or the GCPS are not surprising and are
consistent with other telomere findings in which phenotypes
were not characterized and differentiated by duration, severity,
and persistence of stress.
4.4. Relevance of telomere length and FITT to osteoarthritis
and pain research
Telomeres are dynamic and influenced by the biochemical
environment (cortisol, inflammation, and oxidative stress). Es-
sentially, they are molecular measures of life experience, altered
by persisting biological and psychosocial stress, and to some
degree reflect general health and disease susceptibility.8,27 As
such, telomeres are not specific toOAor chronic pain but seem to
provide a relative indication of whether a system is in balance vs
overloaded. In addition, there is evidence that telomere shorten-
ing may be reduced or buffered by health promoting inter-
ventions14,26,45,46 which could reduce the biological burden
of chronic pain and associated psychosocial stress on the
individual.28
4.5. Limitations and future directions
Although the findings reported are encouraging, the next phase
of investigation requires prospective analysis. The relevance of
telomere length and the FITT index in OA and chronic pain
research will best be determined by the replication of findings
and longitudinal investigations. Second, phenotyping with
Table 5
Relationship between clinical measures and telomere length.
Measures F Value P
WOMAC
Pain 1.32 0.25
Stiffness 1.60 0.21
Physical function 3.30 0.07
Total 2.93 0.09
SPPB
Chair stand 0.01 0.94
Gait 1.96 0.16
Balance 2.59 0.11
Total 0.02 0.90
GCPS
Characteristic pain intensity 0.96 0.33
Total disability points 0.05 0.82
Pain grade 0.12 0.73
Covariates: age, race or ethnicity, sex, site, and knee pain status. SPPB, Short Physical Performance Battery;
GCPS, Graded Chronic Pain Scale; WOMAC, Western Ontario and McMaster Universities Index of
Osteoarthritis.
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comprehensive and detailed biopsychosocial and behavioral
data will be essential to confirm the sensitivity of telomere length
to changes in the OA pain severity experience. Longitudinal data
and access to medical records that provide information
regarding frequency, intensity, and duration of pain would
greatly improve the phenotyping process. Third, confounding
factors that contribute to the pathophysiological mechanisms
may influence findings and warrant further investigation. Fourth,
in this study, 3 domains of FITT were assessed specific to knee
pain experiences. It is anticipated that an FITT index reflective of
the cumulative pain experience in individuals with OA or other
chronic pain conditions might be a more “effective” index than
the typical assessment of a site-specific pain. Fifth, median
splits were used to create the FITT chronic pain severity index.
Although the cut points align with previous findings, inves-
tigations to determine the weighting of domains and actual
clinical ranges would be helpful in better understanding the
characteristics of pain that facilitate biological burden and
accelerated aging. Sixth, little is known regarding the relation-
ship between telomeres and pharmacological management of
pain. Findings on psychotropics and telomeres can provide
guidance to these important future investigations.35 Finally, the
biological burden equation is not unidirectional, as protective
factors can reduce the load of biopsychosocial stress.28,45,46,53
A better understanding of this dynamic multidimensional
relationship will help facilitate efforts to promote resilience and
buffer the biological burden of chronic pain and associated
psychosocial stress, thus promoting more optimal health
outcomes and possibly improved quality of life.
5. Conclusions
Our findings demonstrate accelerated cellular aging with in-
creasing severity of knee OA pain. Importantly, telomere length is
predictive of morbidity and mortality; chronic pain and OA are
related to increasing morbidity and mortality; and now, telomere
length shortening is associated with knee OA chronic pain
severity. In addition, we replicate a chronic pain severity dose–
response pattern in telomere length that was previously
demonstrated in a population-based study investigating an
immune and metabolic risk factor composite.53 Results suggest
theremay be a biological burden associated with chronic OA pain
and clinical measures capturing the frequency, intensity, time or
duration, and extent of body pain which may help elucidate those
changes.
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